Broadfin Capital LLC Has Boosted Adamas Pharmaceuticals INC (ADMS) Position by $7.05 Million

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Broadfin Capital Llc increased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.83% based on its latest 2018Q2 regulatory filing with the SEC. Broadfin Capital Llc bought 281,918 shares as the company’s stock declined 17.64% while stock markets rallied. The hedge fund held 1.42 million shares of the health care company at the end of 2018Q2, valued at $36.60M, up from 1.14 million at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be bullish on the $272.81M market cap company. The stock decreased 0.30% or $0.03 during the last trading session, reaching $9.98. About 412,860 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 9.07% since December 8, 2017 and is uptrending. It has underperformed by 6.55% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $635.22M US Long portfolio, decreased its stake in Zogenix Inc (Put) by 202,380 shares to 335,000 shares, valued at $14.81 million in 2018Q2, according to the filing. It also reduced its holding in Retrophin Inc (NASDAQ:RTRX) by 129,533 shares in the quarter, leaving it with 1.05 million shares, and cut its stake in Mirati Therapeutics Inc (NASDAQ:MRTX).

More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare – Seeking Alpha” on October 05, 2018, also Seekingalpha.com with their article: “Adamas Pharma operating chief bids adieu – Seeking Alpha” published on September 14, 2018, Fool.com published: “Why Adamas Pharmaceuticals, Inc. Stock Sank in September – Motley Fool” on October 12, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: Seekingalpha.com and their article: “Leerink sees 34% upside in Allergan in premarket analyst action – Seeking Alpha” published on November 13, 2018 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Denali’s Positive Results, Novartis’ Substance Abuse Therapy Launch, Medtronic Earnings – Benzinga” with publication date: November 20, 2018.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 4 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Adamas Pharmaceuticals had 5 analyst reports since June 22, 2018 according to SRatingsIntel. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Neutral” rating given on Friday, October 5 by Bank of America. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Friday, June 22 by Mizuho. The rating was downgraded by Mizuho to “Neutral” on Monday, November 5.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.